News & Updates
Filter by Specialty:
START-FIT: TACE + RT + avelumab promising as conversion therapy for locally advanced unresectable HCC
START-FIT, a prospective, single-arm, phase II trial, has found sequential transarterial chemoembolization (TACE) and stereotactic body radiotherapy (SBRT) followed by anti–PD-L1 treatment with avelumab to be a promising strategy for making patients with locally advanced unresectable hepatocellular carcinoma (HCC) amenable to curative treatment.
START-FIT: TACE + RT + avelumab promising as conversion therapy for locally advanced unresectable HCC
18 Jan 2023
Behavioural therapy may improve physical activity, sleep quality in asthma patients
Individuals with asthma may benefit from a behavioural intervention to increase their physical activity (PA), which may lead to improvements in quality of life and sleep, as well as a reduction in asthma and anxiety symptoms, suggest the results of a recent study.
Behavioural therapy may improve physical activity, sleep quality in asthma patients
17 Jan 2023
CVD, mood disorders up risk of dementia in RA patients
Among patients with rheumatoid arthritis (RA), those with clinically active RA, cardiovascular or cerebrovascular disease (CVD), hypertension, depression, and anxiety are at greater risk of dementia, reveals a study. Among CVD events, ischaemic stroke and heart failure are significantly associated with an increased dementia risk.
CVD, mood disorders up risk of dementia in RA patients
17 Jan 2023
Septal reduction reduces HF readmission, improves survival in oHCM patients
Septal reduction therapies (SRT) lower the readmission rates for heart failure (HF) in Medicare patients with obstructive hypertrophic cardiomyopathy (oHCM), a study has shown.
Septal reduction reduces HF readmission, improves survival in oHCM patients
17 Jan 2023
Artificial pancreas yields good results in type 2 diabetes patients
A fully closed-loop insulin delivery system, also known as artificial pancreas, helps improve the management of type 2 diabetes in adults, increasing the time spent in target glucose range by 8 hours per day without promoting hypoglycaemic events as compared with standard insulin therapy, as reported in a study.
